Neoadjuvant androgen ablation in localized carcinoma of the prostate

Cancer Control

Volumn 8, Issue 2, 2001, Pages 155-162

  Kish, Julie A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; FLUTAMIDE; GOSERELIN;

ADJUVANT THERAPY; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; LONG TERM CARE; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RADIATION INJURY; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0035053828     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480100800206     Document Type: Article

References (43)

1. The results of prostate carcinoma screening in the US as reflected in the surveillance, epidemiology and end results program
2. The early detection of prostate carcinoma with prostate specific antigen: The Washington University experience
3. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?
4. Is combined modality therapy appropriate for apparently localized carcinoma of the prostate?
5. Use of neoadjuvant androgen therapy in clinically localized prostate cancer
6. Radical surgery for prostate cancer
7. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
8. Experience with neoadjuvant diethylstilbestrol and radical prostatectomy in patients with locally advanced prostate cancer
9. Neoadjuvant hormone therapy before radical prostatectomy: Update on the Memorial Sloan-Kettering Cancer Center trials
10. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: The first controlled and randomized trial
11. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMO) prostate cancer: The Lupron Depot Neoadjuvant Prostate Cancer Study Group
12. Randomized prospective study - Radical prostatectomy alone vs radical prostatectomy preceded by androgen blockade in cT2b prostate cancer - Initial results
13. A randomized trial of neoadjuvant androgen withdrawal therapy prior to radical prostatectomy: 24 month post-treatment PSA results
14. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer
15. Prolonged neoadjuvant combined androgen blockade leads to a further reduction in prostatic tumor volume: Three versus six months of endocrine therapy
16. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate
17. Natural history of progression after PSA elevation following radical prostatectomy
18. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation
19. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer
20. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors
21. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer
22. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report
23. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients
24. Early prostate cancer: The national results of radiation treatment from the Patterns of Care and Radiation Therapy Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation
25. The role of neoadjuvant androgen deprivation prior to radical prostatectomy
26. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: Implications for dosing schedule and neoadjuvant study consideration
27. Outcome for lymph node dissection negativeT-1b,T-2(A-2,B) prostate cancer treated with external beam radiation therapy in RTOG 77-06
28. Improved survival in patients with locally advanced prostate cancer treated with radio-therapy and goserelin
29. Prognostic factors in carcinoma of prostate: Analysis of RTOG study 75-06
30. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31
31. Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy
32. Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: Preliminary results of RTOG 83-07
33. Effects of intermittent androgen suppression on androgen-dependent tumors: Apoptosis and serum prostate-specific antigen
34. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group
35. Long-term outcome for patients with locally advanced non-metastatic prostate cancer treated with adjuvant hormones and radiation therapy versus radiation therapy alone: Subset analysis of RTOG 85-31 and 86-10. Proceedings of the American Society of Therapeutic Radiology Oncology (ASTRO), San Antonio, Tex.
36. Does radiotherapy add anything to androgen ablation?
37. RTOG Protocol 92-02: A phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate
38. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy
39. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy
40. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
41. Hormonal therapy in the management of prostate cancer: From Huggins to the present
42. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: Results of a phase II study